P

Puma Biotechnology
D

PBYI

3.05500
USD
0.11
(3.56%)
مغلق
حجم التداول
15,489
الربح لكل سهم
0
العائد الربحي
0
P/E
16
حجم السوق
149,837,739
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ALKS
    -0.440
    (-1.61%)
    26.860 USD
    E
    ESPR
    -0.13000
    (-5.62%)
    2.18500 USD
    I
    IMGN
    0
    (0%)
    0.000000 USD
    I
    INCY
    -0.680
    (-1.05%)
    64.390 USD
    J
    JAZZ
    3.940
    (3.57%)
    114.330 USD
    M
    MDGL
    -6.22
    (-2.18%)
    278.97 USD
    N
    NKTR
    -0.10000
    (-7.38%)
    1.25500 USD
    P
    PCRX
    0.090
    (0.44%)
    20.750 USD
    S
    SRPT
    1.650
    (1.16%)
    144.000 USD
الأخبار
المقالات

العنوان: Puma Biotechnology

القطاع: Healthcare
الصناعة: Biotechnology
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.